Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 2/20 | 0.37 |
| ▸ | KDM4B | O94953 | 2/20 | 0.37 |
| ▸ | KDM5C | P41229 | 2/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.37 |
| ▸ | PNP | P00491 | 5/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18521204 | 0.87 | PDPK1 (0.49) | PDPK1ALDH1A1KDM4AKDM4BKDM5C | |
| SCHEMBL14190552 | 0.75 | PDPK1 (0.76) | PDPK1ALDH1A1PNPPARP1 | |
| SCHEMBL7422389 | 0.73 | PDE5A (0.50) | PDPK1HPGDKDM4ERXFP1KDM4A | |
| SCHEMBL21943367 | 0.73 | PDPK1 (0.42) | PDPK1ALDH1A1PNP | |
| SCHEMBL6643757 | 0.72 | PNP (0.56) | PNP | |
| SCHEMBL1945810 | 0.72 | PNP (0.64) | PDPK1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL1948229 | 0.72 | PNP (0.61) | PDPK1PNP | |
| SCHEMBL4128983 | 0.71 | PDE2A (0.40) | ALDH1A1KMT2AKDM4EPARP1 | |
| SCHEMBL1415736 | 0.71 | PNP (0.62) | PNP | |
| SCHEMBL1415550 | 0.71 | PNP (0.62) | PDPK1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099689-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-01-26 | — | — | EP | disclosed |
| WO-2012024419-A2 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | PDE4A, PDE7B, PDE4B | PDPK1 125/4885HPGD 117/4885ALDH1A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.